Subscription period: 13 July 2026 – 27 July 2026
Trading with unit rights: 13 July 2026 – 22 July 2026
Subscription with preferential rights: Eight (8) existing shares held on the record date, 9 July 2026, entitle the holder to one (1) unit right. One (1) unit right entitles the holder to subscribe for one (1) unit, where each unit consists of thirty-three (33) shares and thirty-three (33) warrants of series TO10 issued free of charge
Subscription price: The subscription price in the rights issue amounts to SEK 68.31 per unit, corresponding to SEK 2.07 per share.
Issue proceeds: Upon full subscription in the rights issue, the company may receive gross proceeds of up to approximately SEK 30.0 million before issue costs
Subscription commitments and Underwriting commitments: The rights issue is covered by subscription commitments and guarantee undertakings corresponding to approximately 50.0 per cent
Teckningsoptioner av serie TO10: Each warrant of series TO10 entitles the holder to subscribe for one (1) new share in the Company during the exercise period, which runs from 4 January 2027 to 18 January 2027. The subscription price for subscription of shares through exercise of warrants of series TO10 amounts to SEK 2.07
Lumito has developed a differentiated platform for more sensitive, high-contrast and objective tissue analysis. The company’s product, SCIZYS, addresses important needs in drug development and digital pathology – two markets driven by strong structural growth and an increasing need for more reliable analytical tools.
In 2025 and 2026, Lumito intensified its commercialisation efforts through increased market presence, deeper customer insights, more efficient sales processes and the development of strategic collaborations. These initiatives have strengthened the company’s market position, laid the foundation for future growth and enabled partnerships with key players in tissue analysis. At the same time, Lumito has implemented organisational and operational efficiency measures to reduce its cost base and strengthen financial resilience, without compromising its focus on commercialisation and long-term scalability.
To continue the commercialisation of SCIZYS and capitalise on the momentum that has been built, Lumito is now carrying out the rights issue. The net proceeds are primarily intended to be used to accelerate commercial expansion through the scaling of CRO collaborations, the establishment of collaborations with pharmaceutical companies and increased sales of reagent kits and scanning services with recurring revenue characteristics. In addition, the company intends to strengthen market access and the scientific evidence base through strategic partnerships, pilot studies and collaborations with leading researchers, tissue analysis specialists and Key Opinion Leaders (KOLs).
Upon full subscription in the rights issue, Lumito will receive gross proceeds of approximately SEK 30.0 million before issue costs. The proceeds from the rights issue are intended to be allocated to the following areas:
Lumito may also receive additional proceeds of up to approximately SEK 30.0 million before issue costs upon exercise of the warrants issued in connection with the rights issue, which are intended to be used for the following activities:
Important information
Due to legal restrictions, the information on this section of Lumito AB’s (the “Company”) website is not directed at or accessible to certain persons. We kindly ask you to review the following information and provide the following confirmation each time you wish to access this section of the website. Please note that the terms set out below may be altered or updated and therefore it is important that you review them each time you visit this section of the website.
The information contained in this section of the Company’s website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, United Kingdom, United States or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction, and does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any subscription rights, paid subscribed shares (Sw. Betalda tecknade aktier) or any shares or other securities of the Company (“Securities”) in the Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, United Kingdom, United States or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.
No Securities have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the securities legislation of any state or other jurisdiction of the United States, and thus, Securities may not be offered, subscribed for, exercised, pledged, sold, resold, granted, delivered or otherwise transferred, directly or indirectly, within or to the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. No public offering of the Securities is being made in the United States. The Securities have not been and will not be registered under the applicable securities laws of Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, United Kingdom or any other jurisdiction in which it would be unlawful or would require registration or other measures, and therefore may not be offered or sold directly or indirectly, within or to Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, United Kingdom or any other jurisdiction in which it would be unlawful or would require registration or other measures.
No public offer of Securities is made in any country within the European Economic Area (“EEA”) other than Sweden. In other member states of the European Union (“EU”) or the United Kingdom, such an offer may only be made in accordance with the exemption in the regulation (EU) 2017/1129 (the “Prospectus Regulation”) or Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the “UK Prospectus Regulation”). In other countries in the EEA that have implemented the Prospectus Regulation in their national legislation, such an offer may only be made in accordance with the exemption in the Prospectus Regulation and/or in accordance with each relevant implementing measure. This portion of the website is directed only at persons in countries within the EEA or in the United Kingdom who are “qualified investors” within the meaning of Article 2(e) of the Prospectus Regulation or the UK Prospectus Regulation. In other countries in the EEA that have not implemented the Prospectus Regulation in their national legislation, such an offer may only be made in accordance with the applicable exemption in national legislation.
With respect to the United Kingdom, information and documentation contained on this portion of the website is directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”) or (iii) persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations etc.”) of the Order or (iv) certified high net worth individuals and certified and self-certified sophisticated investors as described in Articles 48, 50, and 50A respectively of the Order or (v) persons to whom the information may otherwise be lawfully communicated (all such persons together being referred to as “relevant persons”). The information mentioned in any document on the website will only be available to and directed and distributed to relevant persons. Any person whom is not a relevant person should not act or rely on the documents or any of its contents.
Access to the information and documents contained on this section of the Company’s website may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information and documents. All persons residing outside of Sweden who wish to have access to the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this section of the Company’s website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been obtained outside Sweden. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
I certify that:
I am resident outside and physically present outside of the Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, United Kingdom, United States or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction; and
I am resident and physically present (a) in Sweden or (b) outside of Sweden and each of the jurisdictions referred to in item (1) above and, in that case, I am authorised to access the information and documents on this website without being subject to any legal restriction and without any action required by the Company; and
I will not distribute or otherwise send any information contained on this section on the Company’s webpage to any person resident in, or physically present in, any of the jurisdictions referred to in item (1) above; and
I have read, understand and agree to comply with the restrictions set forth above.